NOT-CA-20-043: Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)

The NCI Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs encourage applications from small businesses with NCI-funded active NCI SBIR/STTR awards that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19) in cancer patients, cancer survivors, and in the general population. A compelling rationale should be presented and linked to an appropriate research plan to generate data in support of the new proposed use. Areas of interest include but not limited to:

  • Adapting the use of cancer diagnostics and diagnostic technologies and platforms for diagnosing the virus, infection, and potential immunity against the virus rapidly at the point of care setting;
  • Repurposing or expanding use of cancer vaccines, vaccine candidates, and other technologies for prevention of, and/or protection from SARS-CoV-2 infection;
  • Repurposing or expanding the use of cancer therapeutics and therapeutic candidates for the treatment of COVID-19 and the management of severe symptoms.

Applicants are strongly encouraged to contact the NCI Program Director of the parent award to discuss potential applications and whether urgent competitive revision applications or administrative supplement requests are more appropriate for the proposed research.

Sponsor or Type

Subscribe to the UArizona Impact in Action newsletter to receive featured stories and event info to connect you with UArizona's research, innovation, entrepreneurial ventures, and societal impacts.

Subscribe now